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Abstract
Background: Genome-wide association studies (GWAS) have revealed many susceptibility loci for complex genetic
diseases. For most loci, the causal genes have not been identified. Currently, the identification of candidate genes is
predominantly based on genes that localize close to or within identified loci. We have recently shown that 92 of
the 163 inflammatory bowel disease (IBD)-loci co-localize with non-coding DNA regulatory elements (DREs).
Mutations in DREs can contribute to IBD pathogenesis through dysregulation of gene expression. Consequently,
genes that are regulated by these 92 DREs are to be considered as candidate genes. This study uses circular
chromosome conformation capture-sequencing (4C-seq) to systematically analyze chromatin-interactions at IBD
susceptibility loci that localize to regulatory DNA.
Results: Using 4C-seq, we identify genomic regions that physically interact with the 92 DRE that were found at IBD
susceptibility loci. Since the activity of regulatory elements is cell-type specific, 4C-seq was performed in monocytes,
lymphocytes, and intestinal epithelial cells. Altogether, we identified 902 novel IBD candidate genes. These include
genes specific for IBD-subtypes and many noteworthy genes including ATG9A and IL10RA. We show that expression
of many novel candidate genes is genotype-dependent and that these genes are upregulated during intestinal
inflammation in IBD. Furthermore, we identify HNF4α as a potential key upstream regulator of IBD candidate genes.
Conclusions: We reveal many novel and relevant IBD candidate genes, pathways, and regulators. Our approach
complements classical candidate gene identification, links novel genes to IBD and can be applied to any existing
GWAS data.
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Background
Inflammatory bowel disease (IBD) is an inflammatory
disorder of the gastro intestinal tract with an intermit-
tent, chronic, or progressive character. Studies on the
pathogenesis of IBD have elucidated the involvement of
a broad range of processes that mainly regulate the
interaction between the intestinal mucosa, the immune
system, and microbiota [1]. A role for genetics in the
pathogenesis of IBD has been established through twin-
based, family-based, and population-based studies [1].
Subsequently, a substantial effort to identify genetic ele-
ments involved in the IBD pathogenesis followed. In this
respect, multiple genome-wide association studies
(GWASs) have been performed over the past years [2–5].
In these studies, common genetic variants (single nucleo-
tide polymorphisms (SNPs)) are assayed across the whole
genome in search of variants that are significantly over-
represented or under-represented in patients compared to
healthy controls. Although GWASs have revealed many
IBD-associated loci, for most loci the causal genes that led
to the associations have not been identified. Furthermore,
the majority of IBD-associated SNPs are located in non-
coding DNA and therefore cannot be causal in the sense
that they directly lead to amino acid changes at the pro-
tein level [2–4, 6–9]. Therefore, these SNPS are generally
thought to be markers for disease-causing variants in
nearby genes. This model is used in classical approaches
for candidate gene identification. These approaches are
mainly based on the selection of genes that have shared
functional relationships and are localized in the vicin-
ity of the identified loci [10, 11]. This has led to the
identification of crucial genes and pathways involved
in the IBD pathogenesis [12]. However, over the past
decade it has been established that besides genes, the
human genome consists of many other functional ele-
ments in the non-protein-coding regions. These regions
of the genome can play a role in the pathogenesis of com-
plex diseases. As such, many types of DNA regulatory ele-
ments (DRE), especially enhancer elements, are involved
in establishing spatiotemporal gene expression patterns in
a cell type-specific manner [13]. These elements are
crucial in the regulation of developmental processes and
in maintaining cell type-specific functionality. It is
therefore now widely appreciated that part of the GWAS
associations is due to sequence variation in DRE, but this
information has largely been ignored in candidate gene
identification [9, 14–18].
We have recently shown that 92 of 163 IBD GWAS
susceptibility loci localize to DRE (identified through the
presence of H3K27Ac in relevant cell types) [9]. DRE are
involved in transcription regulation and establishing cell
type-specific expression patterns [19]. The genes that are
regulated by the IBD-associated elements are likely to
play a role in IBD and can therefore be considered as
IBD candidate genes. This information has not been
used in previous candidate gene approaches, because the
identification of these genes comes with several hurdles.
Since regulatory elements can regulate genes via chro-
matin–chromatin interactions that comprise up to 1 Mb
[20, 21], these genes cannot be identified based on their
linear distance from the regulatory regions. Classical
methods for candidate gene identification, that take
regulatory mechanisms into account, have mainly been
restricted to computational approaches [14, 16, 22, 23].
So far, a limited number of studies have shown the value
of using physical interactions between regulatory ele-
ments and the genes they regulate through studying the
three-dimensional (3D) nuclear conformation chromatin
interactions in GWAS interpretation. These studies ana-
lyzed either single interactions (3C) or many-vs-many
interactions (Hi-C) and were performed in colorectal
cancer, auto-immune diseases, and multiple other dis-
eases [24–27]. In contrast to these approaches we make
use of circular chromosome conformation capture-
sequencing (4C-seq), thereby increasing the number of
analyzed interactions compared to 3C and increasing the
resolution compared to Hi-C. Our study provides the
first systematic analysis of chromatin interactions
between disease-associated DRE and candidate genes in
IBD. We have identified 902 novel IBD candidate genes,
consisting of many noteworthy genes, for example
IL10RA, SMAD5, and ATG9A.
Results
Genes interacting with DRE at IBD associated loci
A meta-analysis on GWASs performed in IBD resulted in
the confirmation of 163 susceptibility loci [3]. We have
recently shown that 92 of these 163 loci overlap with
enhancer elements (regulatory elements that enhance
transcription) that are active in relevant cell types for IBD
(i.e. intestinal epithelial cells and immune cells) [9]. We
now use this information to identify novel IBD candidate
genes. We do so by identifying the genes that are regu-
lated by these 92 regulatory elements. Since the regulated
genes cannot be pinpointed by studying the linear
organization of the susceptibility loci, we assayed the 3D
conformation of these loci (Fig. 1). The effect of common
variants, especially those in regulatory elements, is rela-
tively mild. Therefore, it is very unlikely that a single com-
mon variant will ablate or create a whole regulatory
region and its 3D interaction [28]. By the same reasoning,
we do not expect that the 3D interactions in patients will
be fundamentally different compared to healthy controls
or cell lines. However, regulation of genes can be genotype
specific [16], which demands for the identification of
genes that are dysregulated in IBD. For these reasons, we
decided on an experimental setup where we assay chro-
matin conformation in healthy control cells and a cell line,
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to identify genes that can be dysregulated in IBD under
pathological conditions. Therefore, we have performed 92
high resolution 4C-seq experiments to cover all individual
IBD susceptibility loci that overlap DRE in three cell types,
thereby creating 276 individual chromatin interaction
datasets. This way, we could identify all genes that physic-
ally interact with the regulatory elements that are found at
IBD associated loci. As the activity of enhancers is known
to be cell type-specific [19], we assayed chromatin interac-
tions in monocytes (i.e. CD14+ fraction of PBMCs),
lymphocytes (i.e. CD14- fraction of PBMCs), and in an in-
testinal epithelial cell line (DLD-1, derived from colorectal
adenocarcinoma).
4C-seq identifies different sets of candidate genes in
different cell types
The candidate genes that we report here all meet the fol-
lowing criteria: (1) the enhancer element physically inter-
acts with the candidate gene (p > 10–8); (2) the enhancer
element is active in the assayed cell type (i.e. the associ-
ated variant or a variant in LD co-localizes with the his-
tone mark H3K27Ac) [9]; and (3) the candidate gene is
expressed in the assayed cell type (log2(RPKM) > –0.5).
With this approach we identified 1409 candidate genes:
923 genes in monocytes, 1170 in lymphocytes, and 596 in
DLD-1 cells, of which 796 were shared by two or more
cell types and 810 were found in only one cell type (Fig. 2a
and b). We identified 902 IBD candidate genes that have
not been reported by GWASs before (Table 1, Additional
file 1: Table S2). Of the 92 studied loci, 22 are associated
to only one of the IBD subtypes (11 to Crohn’s disease, 11
to ulcerative colitis). The candidate genes that were identi-
fied for these loci might contribute to the mechanisms
that lead to the subtype-specific phenotypes. Interestingly,
for two loci on chromosome 7 that give separate GWAS
signals for CD (rs10486483) and UC (rs4722672), the 10
candidate genes that were identified for this CD locus
were also found in the UC locus. This implies that in some
cases, although the genetic risk factor is different between
the subtypes, the mechanisms that underlie the genetic
risk can share downstream components. Notably, this UC
locus is active in intestinal epithelium, whereas the CD
locus is not, which resulted in the identification of add-
itional candidate genes for rs4722672 that are UC-specific
(Table 1). Among the identified candidate genes are many
noteworthy genes that have been implicated in the IBD
pathogenesis, but that were never identified through
GWAS associations (Table 2 [29–35]). We have now iden-
tified these novel candidate genes that have been missed
by classical approaches for candidate gene identification.
As expected, based on their common hematopoietic
origin, the two immune cell types show larger overlap
compared to DLD-1 cells (Fig. 2b, Additional file 2:
Figure S5). With a median enhancer-to-gene distance of
Fig. 1 3D nuclear organization in candidate gene identification. a The linear organization of the genome does not provide sufficient information
to predict which gene is regulated by an enhancer of interest. b Genes that are regulated by an enhancer form a 3D nuclear interaction. c The
4C-seq technique captures the 3D conformation and results in a signal around the gene that was interacting with the viewpoint (i.e. the SNP).
For a detailed explanation of the 4C-seq procedure we refer to the published 4C protocol [54]. In this study, the analysis of the 3D conformation
of chromatin will reveal which genes interact with an enhancer that is found at an IBD-susceptibility locus. The 4C analysis of a locus will show
an interaction signal that can be mapped to the gene with which the interaction was formed. Therefore, 4C-seq can be used as a tool to use
information on DNA regulation for candidate gene identification
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261, 370, and 354 kbp in DLD-1, lymphocytes, and
monocytes respectively, a large proportion of the genes
we report are found outside the GWAS susceptibility
loci (Fig. 2c). Notably, some of the interactions between
IBD loci and candidate gene span over 5 Mb. For ex-
ample, rs925255 shows a significant (p = 6.068 × 10–9)
physical interaction with TANK (TRAF family member-
associated NF-κB activator), a gene that is localized
30 Mb from this locus (Additional file 1: Table S2).
Validation and reproducibility of 4C-seq data
To validate the reproducibility of our data, we prepared
a 4C template from lymphocytes from a different donor
and performed 4C-seq for the 92 regions on this mater-
ial. Additional file 2: Figure S4A shows that 91% of the
candidate genes that are identified in the replicate dataset
were also identified in the dataset that is used throughout
this study. This demonstrates the reproducibility of the 4C
technique, not only in technical, but also in biological
duplicates. These results are in line with studies that have
previously shown that in 3C-based methods, results from
biological duplicates are highly reproducible [36]. Further-
more, we validated the reproducibility of our data by inter-
secting the 4C datasets with Hi-C datasets that were
created in CD34+ leukocytes and a lymphoblastoid cell
line [25]. This confirmed a high reproducibility by show-
ing that 99% (CD34+) and 87% (lymphoblastoid) of the
genes that were found by Hi-C were also found in our 4C
data (Additional file 2: Figure S4B).
Identified candidate genes are actively expressed
We reasoned that genes that are truly regulated by active
enhancers in vivo would, on average, be more highly
expressed than other genes within the region of the 4C
signal. The quantitative examination of expression levels
and histone modifications that mark active enhancers
and promoters confirmed that the genes that were
detected by our method indeed are more actively
Fig. 2 Candidate gene characteristics. a Flowchart of filtering steps that were performed to identify IBD candidate genes (4C interactions with
p > 10–8; locus activity based on the co-localization of the associated variant or a variant in LD with H3K27Ac; gene expression: log2(RPKM) > –0.5).
The number of remaining genes after each step is depicted in the corresponding arrow. b A Venn diagram of the candidate genes (that meet all
three criteria) identified in the three separate cell types. The surface of the circles corresponds with the numbers of genes that are unique for one
cell type and with the genes that where only two cell types overlap. The number of genes shared by all three cell types is depicted in the center
of the diagram. The differences between DLDs and the immune cells is not solely due to shared active enhancers between monocytes and
lymphocytes that are inactive in DLDs. To address this, Additional file 2: Figure S5 depicts a Venn diagram of all genes interacting with one of all
(92) assayed viewpoints. These results confirm the ability of 4C-seq to detect cell type specific chromatin-chromatin interactions. c Distribution of
the distance between the reported candidate genes and the viewpoints. The majority of the genes is located several hundreds of kilobases away
from the susceptibility locus
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transcribed than all other genes (also than genes that
were not detected by 4C and are found in the same gen-
omic region, Additional file 2: Figures S6 and S7). These
results support the detection of functional interactions
by the 4C-seq approach that was executed here. Further-
more, we assessed “possible” insulator elements (i.e.
insulators occupied by CTCF protein) between the 92
DRE and the candidate genes. Interestingly, the majority
of interactions bypasses several CTCF sites and numerous
interactions skip over 50 sites bound by CTCF (Additional
file 2: Figure S8). In addition, genes that do not interact
with the 4C viewpoint do not seem to have more CTCF
sites between the viewpoint and their promoter compared
to the interacting genes (Additional file 2: Figure S8). This
Table 1 4C-seq output per locus
This table shows the 4C output for each associated IBD locus that overlaps an active regulatory element based on the presence of H3K27Ac and is arranged
based on the GWAS association of the loci to either Crohn’s disease (CD), ulcerative colitis (UC), or both (IBD). The positions are given as in the GWAS in which the
association was found [3] and are relative to human reference genome GRCh37. Depicted are the name of the SNP and the key novel genes that were identified
at that locus. The numbers refer to the number of novel genes that were identified at that locus and, between brackets, the total number of candidate genes
identified at that locus
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is in line with observations from Hi-C datasets where
82% of long-range interactions bypass at least one
CTCF site [25].
Previously, insulator regions have been shown to
prevent enhancer-gene interactions [37]. We there-
fore investigated whether assessment of the CTCF
binding can be used as an alternative to the 4C
method by predicting the borders of the regions in
which our candidate genes were found. We conclude
that CTCF binding information cannot be used as an
alternative for the 4C-based candidate gene approach
presented here.
4C-seq candidate genes have SNP-dependent expression
profiles
We hypothesize that the candidate genes that we identify
are contributing to the IBD pathogenesis via impaired
transcription regulation caused by variants in DRE. To
test this hypothesis, we studied whether 4C-seq candi-
date genes show different expression profiles in different
genetic backgrounds (i.e. in individuals that carry the as-
sociated SNP versus individuals that do not) through
eQTL analyses [23]. We performed two different ana-
lyses in separate databases. First, we used the GTEx
database [38] to test whether our approach is able to de-
tect the eQTLs that are present in the intestinal
epithelium (colon-sigmoid, colon-transverse, terminal
ileum) and whole blood [38]. We performed an eQTL
look-up of the 92 IBD-associated SNPs in these tissues
and found 50 genes with a SNP-dependent expression
profile. Interestingly, all of the 50 genes were identified
by our 4C-seq approach (Additional file 3: Table S4).
Second, we made use of another eQTL database
(STAGE) [39] and explored the presence of candidate
genes among the genes that were found to have expres-
sion levels that are dependent on the interacting SNP
genotype in white blood cells. This revealed 10 candidate
genes that have an eQTL in the STAGE database. Next,
we analyzed all non-interacting genes within 2 Mb from
the 4C viewpoint (Additional file 3: Table S4). In con-
trast to the interacting genes, none of the non-
interacting genes showed genotype-dependent expres-
sion in the same database. These findings altogether
support the capability of our method to identify the can-
didate genes of which the expression regulation is
dependent on IBD-associated genomic variants.
4C-seq gene set is enriched in genes involved in
inflammation in IBD patients
After demonstrating that our method enables the identi-
fication of novel IBD candidate genes that are likely sub-
ject to SNP-dependent expression levels, we examined
whether the genes we report here are involved in the
major pathogenic process in IBD, namely intestinal
inflammation. To address this, we performed a GSEA
[40] in which we used RNA expression data of intestinal
biopsies from IBD patients [41]. We compared expres-
sion levels in inflamed versus non-inflamed intestinal bi-
opsies and tested whether the 4C-seq candidate genes
were enriched among the differentially expressed genes.
This analysis shows that all three 4C gene sets (mono-
cytes, lymphocytes, and intestinal epithelium) are highly
enriched (p < 0.001) for genes that are upregulated upon
intestinal inflammation in IBD patients (Fig. 3). These
results support the role of the candidate genes reported
here in intestinal inflammation in IBD.
Chromatin interactions reveal IL10RA and ATG9A as novel
IBD targets
IL10RA is one of the newly identified candidate genes.
Previously, sequence variants in genes encoding the two
subunits of the interleukin 10 receptor, IL10RA and
IL10RB, were found to cause severe early onset IBD in a
Mendelian fashion [32]. Our 4C datasets reveal that
IL10RA interacts with an IBD-associated enhancer elem-
ent in peripheral blood lymphocytes (p = 4.1 × 10–10).
Since IL10RA is located ~1 Mbp upstream of the associ-
ated SNP (rs630923) and is separated from the SNP by
multiple haploblocks (Fig. 4a), this gene has not been
identified through classical candidate gene approaches.
Table 2 Noteworthy novel candidate genes
ATG9A: ATG9A encodes autophagy related protein 9A. Autophagy plays
an import role in host defense by eliminating pathogens. ATG-family
member ATG16L1 has previously been associated with Crohn’s disease [29].
BATF: Basic leucine zipper transcription factor ATF-like (BATF) belongs to
the activator protein 1 family that is involved in transcription regulation in
all immune cells. Batf-deficient mice do not develop Th17 cells and do not
produce IL17. Furthermore, BATF regulates cell type specific gene
expression in Th2 cells, germinal center B-cells, and T-follicular helper
cells [30].
CD46/CD55: CD46 (also known as MCP) and CD55 (also known as DAF)
are regulatory proteins expressed on surface membranes. These proteins
protect the host from autologous complement-mediated injury upon
activation of the complement cascade. Daf-deficient mice show
increased epithelial damage upon induction of colitis, delayed healing,
and elevated expression of proinflammatory cytokines [31].
IL10RA: The IL10-receptor consists of the two subunits IL10RA and
IL10RB. Sequence variants in genes encoding these two subunits are
known to cause severe very early onset IBD in a monogenic fashion
[32]. While the association of IL10RB with the complex form of IBD was
reported by GWASs, the link with IL10RA was so far missing.
SMAD5: SMAD5 is a downstream effector in BMP signaling. SMAD5
expression was found to be downregulated in intestinal cells of IBD
patients. Furthermore, conditional depletion of Smad5 in mice results in
increased susceptibility for development of colitis upon DSS-induction
(dextran sulfate sodium) [34
].
IL10RA interleukin 10 receptor subunit alpha, IL10RB interleukin 10 receptor
subunit beta, Th17 cells T-helper 17 cells, Th2 cells T-helper 2 cells, SMAD
named after their homologous genes Mothers Against Decapentaplegic (MAD)
and the Small Body Size protein (SMA) in Drosophila and C. Elegans, respectively,
CD complement-decay accelerating factor, MCP membrane co-factor protein,
DAF decay accelerating factor
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The enhancer element that co-localizes with rs630923 is
active in lymphocytes, but not in monocytes and intestinal
epithelial cells (i.e. H3K27Ac marks are present only in
lymphocytes). These results imply distinctive and cell
type-specific regulatory pathways for IL10RA expression
in immune cells. Besides IL10RA, we identified 12 candi-
date genes that are part of the IL10 signaling pathway
(Fig. 4b), three of which are novel candidate genes
(IL10RA, IKBKE, MAP3K7). These results confirm and
further establish the important role of IL10 signaling in
IBD.
Furthermore, we identified ATG9A (autophagy-related
gene 9A) as a novel candidate gene, as its transcriptional
start site is physically interacting with an enhancer elem-
ent in the proximity of rs2382817 in DLDs and mono-
cytes (p = 7.891 × 10–13 in monocytes, p = 9.787 × 10–12
in DLDs, Additional file 2: Figure S9). ATG9A is known
to be involved in the generation of autophagosomes.
Furthermore, ATG9A has been shown to dampen the
innate immune response that occurs in response to mi-
crobial dsDNA. ATG9A knockout mice show enhanced
expression of IFN-β, IL6, and CXCL10 upon exposure to
microbial dsDNA [42]. This gene is furthermore of inter-
est to IBD, because the association of other autophagy
genes to IBD is well established [6, 43, 44]. For example,
patients that are homozygous for the ATG16L risk allele
show Paneth cell granule abnormalities [45]. Based on the
role ATG9A plays in responding to microbial dsDNA and
the role ATG16L plays in Paneth cell degranulation, it is
possible that ATG9A contributes to the IBD pathogenesis
in monocytes and intestinal epithelial cells via distinct
mechanisms.
Pathway analysis shows cell type-specific results
Besides studying the individual associated loci and the
genes they regulate, we aimed to elucidate the pathways
in which the IBD candidate genes are involved. Since
our approach enables us to determine both IBD candi-
date genes and the cell type in which they are likely
dysregulated, we analyzed the pathogenic processes that
are possibly involved in monocytes, lymphocytes, and in-
testinal epithelial cells. Therefore, we performed separate
pathway analyses on the datasets generated in these
three different cell types. This revealed that the enriched
pathways in the two immune cell types are mainly simi-
lar to each other, whereas the enrichment in epithelial
cells shows different pathways (Fig. 5, Additional file 4:
Table S5). Notably, IL10 signaling was found to be highly
enriched in the intestinal epithelium dataset. This
implies that the members of this pathway are possibly
dysregulated in this cell type. As this pathway is also
enriched in the immune cells (Additional file 4: Table
S5), it is likely that the contribution of IL10 signaling to
the IBD pathogenesis can be found in the interplay
between the intestinal epithelium and immune cells.
Furthermore, several JAK/STAT and Interferon signaling
pathways were highly enriched in both monocytes and
lymphocytes. JAK-STAT is a common signaling pathway
used by many cytokines. Dysregulation of the JAK-STAT
pathway can lead to a plethora of immune diseases [46].
Fig. 3 GSEA for candidate genes in intestinal inflammation in IBD. The figure shows the GSEA for the candidate genes reported in monocytes,
lymphocytes, and DLDs. Genes that are upregulated (red) in inflamed compared to non-inflamed biopsies are plotted to the left of the x-axes,
downregulated genes (blue) on the right. 4C-seq gene sets are significantly (p < 0.001) enriched for genes that are upregulated in the inflamed
intestine of IBD patients (reflected by positive normalized enrichment score, NES). Enrichment score (ES) reflects the degree to which the 4C-seq
genes sets are over-represented at the differentially expressed genes in intestinal biopsies. The nominal p value and the normalized enrichment
score (NES, normalized for the size of the gene sets) are shown below each graph
Meddens et al. Genome Biology  (2016) 17:247 Page 7 of 15
For example, tissue specific disruption of STAT3 is
known to cause an IBD-like phenotype in mice [46]. The
high enrichment of many pathways that are relevant to
IBD in the datasets of the separate cell types, supports
the relevance of approaches that take cell type-specific
role for candidate genes into account.
Hepatocyte nuclear factor 4α (HNF4α) is a potential key
regulator of the IBD candidate genes
The 4C-seq approach reveals candidate genes based on
their physical interaction with active regulatory regions.
Transcription factors are important mediators in activat-
ing expression from active regulatory regions. Therefore,
we aimed to determine which upstream regulators are
involved in the regulation of transcriptional activity of
the IBD candidate genes. We used an in silico analysis
that determines which factors regulate expression from
the candidate genes and which sets of genes that are
regulated by a certain upstream regulator are enriched
in our cell type-specific datasets. This analysis shows
many significantly over-represented upstream regulators
(Fig. 6a, Additional file 5: Table S6), including numerous
transcription factors. Notably, HNF4α is highly enriched
in all three cell types. HNF4α is a transcription factor
that belongs to the nuclear hormone receptor superfamily
[47]. Recently, the HNF4α-locus was associated to IBD
Fig. 4 IL10RA is a novel IBD candidate gene. a The 4C signal from the rs630923 locus in lymphocytes; signal on the y-axis is depicted as the
percentage of fragends covered per pixel. Black bars indicate significant 4C signal (p < 10–8); all coding genes located in this region are shown.
The TSS of IL10RA co-localizes with a distant significant signal (~1 Mb from the viewpoint). Rs630923 and IL10RA localize to different haploblocks,
meaning these regions do not co-segregate. b A network that consists of members of the IL10 signaling pathway. Red dots represent novel IBD
candidate genes, orange dots represent candidate genes that were identified by 4C-seq as well as by GWAS, blue dots represent previously
reported candidate genes that were not identified in the 4C-seq dataset, and black dots represent members of the IL10 pathway that have not
been associated to IBD. Although many genes of the IL10 signaling pathway have been reported previously, we complement the network with
three novel candidate genes including IL10RA
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through a GWAS [48]. Mouse studies revealed that during
intestinal inflammation, HNF4α has a reduced ability to
bind to active enhancers and that Hnf4α knock-out mice
spontaneously develop colitis [49, 50].
Our study confirms that many genes that are likely
dysregulated in IBD are regulated by HNF4α. Further-
more, HNF4α was found to be one of our candidate
genes that was identified by a distal interaction with
rs6017342 in intestinal epithelial cells (Additional file 1:
Table S2). Upon exposure of intestinal organoids to
bacteria lysate, we found that the epithelial response
is characterized by a marked upregulation of both the
NF-κB pathway and HNF4α (Fig. 6b). The kinetics of
HNF4α expression upon epithelial responses and the
enrichment of HNF4α-regulated genes among the IBD
candidate genes propose HNF4α as a potential key
regulator in IBD.
Discussion
This study shows that using chromatin interactions for
GWAS interpretation reveals many novel and relevant
candidate genes for IBD. Specifically, we have intersected
data on chromatin interactions, mRNA expression, and
H3K27Ac occupation data (marking active enhancer
elements) to identify IBD candidate genes. By applying
4C-seq to cell types involved in IBD, we revealed 902
novel candidate genes, consisting of multiple noteworthy
genes like SMAD5, IL10RA, and ATG9A. Notably, many
novel genes were located outside the associated loci.
There are multiple ways that can be used to identify
significant interactions in 4C-seq datasets and none of
these methods offer the ideal solution for all interaction
ranges (long, short, inter-chromosomal), resolutions, and
dynamic ranges of signal [51, 52]. In this study, we have
selected a method that, to our opinion, provides a good
balance between the specificity and sensitivity for inter-
actions spanning up to several megabases. In order to
reduce the amount of false-positive findings, we chose to
use a stringent cutoff (p ≤ 10–8).
The identification of functional DRE–gene interactions
is further established through the overlap of the candi-
date gene sets identified in the different cell types. Intes-
tinal epithelial cells are developmentally and functionally
very distinct from cells with a shared hematopoietic
Fig. 5 Pathways in IBD. This figure shows the pathways that are most highly enriched among the identified candidate genes in the three separate cell
types. Bars correspond with the –Log of the p value, the dashed line indicates the threshold for significance. Numbers between the brackets show
(amount of pathway members in dataset/total amount of pathway members). Pathway analyses were performed using Ingenuity Pathway Analysis
(IPA, see “Methods”). All significantly enriched pathways can be found in Additional file 3: Table S4
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origin, in that context monocytes and lymphocytes are
more alike. These differences in overlapping background
are reflected by the sets of candidate genes identified in
the different cell types. Specifically, lymphocytes and
monocytes shared a large part of the candidate genes,
whereas intestinal epithelial cells showed a more distinct
set of genes (for example, monocytes share 42% and 8%
of candidate genes with lymphocytes and DLD-1,
respectively; Fig. 2a and Additional file 2: Figure S5).
Although this approach gives a general overview of the
contribution of lymphocytes to the IBD pathogenesis, it
does not enable to discriminate between mechanisms in
lymphocyte subsets. Analyzing a pool of cell types also
decreases the sensitivity of the detection of candidate
genes that are specific to a subset of cells. Therefore, in
future approaches, 4C datasets for specific lymphocyte
subtypes can provide more insight into the contribution
of each of these cell types to the IBD pathogenesis. Fur-
thermore, since UC is limited to the colon and CD can
occur throughout the intestine, creating a 4C dataset
from epithelium derived from different parts the intes-
tine (i.e. duodenum, jejunum, ileum, and colon) might
help to discriminate between the UC and CD specific
pathogenic processes.
We examined the presence of eQTLs among the IBD-
associated SNPs and the 4C-seq candidate genes. These
analyses confirm that our approach is capable to pick up
every candidate gene that was found to have SNP-
dependent expression levels in tissues relevant for IBD.
As expected based on the two eQTL databases that were
used, not all 4C-seq candidate genes we found to have a
SNP-dependent expression pattern. This is (at least in
part) due to the highly context-specific nature of SNP-
dependent differential expression of many eQLTs [53].
While eQTLs are usually identified at one specific cell
state [53], many SNP-dependent expression patterns are
only present under specific conditions (i.e. developmental
stages, presence of activating stimuli, etc.), resulting in a
high false-negative rate of eQTL detection. For example,
many 4C-seq candidate genes might be differentially
expressed between genotypes in the presence of pro-
inflammatory stimuli. Our findings both confirm that our
assay enables to detect genes with a SNP-dependent ex-
pression profile and underlines the need of chromatin-
based techniques to identify the genes that are missed by
eQTL analyses.
By using GSEA we show that the 4C-seq candidate
genes are highly enriched among genes that are upregu-
lated in inflamed intestinal biopsies from IBD patients.
Since the GSEA compares inflamed versus non-inflamed
intestinal tissue within patients, we cannot determine
what the baseline difference in expression is between
Fig. 6 Upstream regulators of IBD candidate genes. a The charts show the upstream regulators of the identified IBD candidate genes in the
separate cell types. Bars correspond with the –Log of the p value, the dashed line indicates the threshold for significance. The analyses were
performed using Ingenuity’s Upstream Regulator Analysis (see “Methods” for more information). All significantly enriched upstream regulators can
be found in Additional file 4: Table S5. b Relative RNA expression before (–) and upon (+) exposure of human intestinal organoids to microbial
antigens. Data were normalized to β-ACTIN mRNA abundances. HNF4α and NF-κB are upregulated upon expose. HNF4α hepatocyte nuclear factor
α, KAT6A K (lysine) acetyl transferase 6A, COMMD3-BMI1 naturally occurring read-through transcription between the neighboring COMM
domain-containing protein 3 and polycomb complex protein BMI-1, ASXL1 additional sex combs like transcriptional regulator 1, TP53 tumor protein
p53, IL4 Interleukin 4, CD40LG CD40 ligand, TCR T-cell receptor, GnRN gonadotropin releasing hormone, ESR1 estrogen receptor 1
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patients and healthy controls. Although the fact that a
gene is upregulated upon inflammation does not show a
causal relation between the (dys)regulation of that gene
and the IBD phenotype, it shows the involvement of the
novel 4C-seq candidate genes in IBD.
We have shown that pathway-enrichment and up-
stream regulator-enrichment algorithms can be used
to interpret and prioritize this large candidate gene
dataset. Interpretation of the 4C-seq data can be fur-
ther optimized by using this data in a quantitative
manner (i.e. correlating peak strength instead of using
a cutoff value for peak calling). However, as with all
approaches for candidate gene identification, further
validation is needed to identify the causal genes for
IBD. The first step towards this confirmation will in
this case consist of revealing the dysregulation of the
candidate gene expression upon alteration of the
enhancer function in vivo.
We have profiled the chromatin interactions in pri-
mary cells from healthy controls and a cell line, to create
a profile of the genes that physically interact with the
IBD susceptibility loci under normal conditions in per-
ipheral immune cells derived from healthy individuals
and in an intestinal epithelium-derived cell line. As the
effects of common variants in regulatory regions are
relatively mild, it is improbable that a single common
variant that is present in an IBD patient will ablate or
create a whole regulatory region and its 3D interaction
[39]. We therefore do not expect that the identification
of candidate genes in cells derived from patients will re-
veal a substantial number of additional interactions. On
the other hand, these variants are expected to cause dys-
regulation of the candidate genes and thereby contribute
to the disease, possibly under very specific conditions,
i.e. during certain stages of development or in presence
of specific stimuli [16, 53].
Our study provides a proof of principle for the usage of
chromatin–chromatin interactions for the identification of
candidate genes. The approach presented here comple-
ments, but does not replace, previously reported ap-
proaches for candidate gene identification [11]. Candidate
gene prioritization models for GWASs currently use mul-
tiple types of information, for example protein–protein in-
teractions, expression patterns, and gene ontology. We
propose that these algorithms should take chromatin in-
teractions into account to optimize gene prioritization.
Conclusions
We have used 4C-seq to study chromatin interactions at
loci that have been associated to IBD through GWASs
using 4C-seq in cell types that are involved in the pa
thogenesis of IBD we identified 902 novel candidate
genes, consisting of multiple noteworthy genes like
SMAD5, IL10RA, and ATG9A.
We conclude that 4C-seq and other 3C-derived methods
can be applied to candidate gene identification in diseases
with a complex genetic background and complement the
classical candidate gene identification approaches.
Methods
Cell culture
DLD-1 cells were cultured in RPMI-1640 with 10% FCS
and standard supplements. Cells were harvested for 4C
template preparation by trypsinization at 60–80%
confluence.
Monocyte and peripheral blood lymphocyte (PBL) isolation
Peripheral blood was collected from two healthy donors
(one for monocyte isolation, one for PBL isolation) in
sodium-heparin tubes. Peripheral blood mononuclear
cells (PBMCs) were isolated by Ficoll-Paque gradient
centrifugation. PMBCs were incubated with magnetic
CD14+ microbeads (Milteny, order no. 130-050-201)
according to the manufacturer’s manual. Thereafter cells
were magnetically separated by the AutoMACS™ Separator;
the negative fraction consisted of PBLs, the positive fraction
of monocytes.
Circular chromosome conformation capture: sequencing
Template preparation
For each cell type, one 4C-template was prepared.
4C-chromatin preparation, primer design, and library
preparation were described previously [54]. 10 × 106
cells were used for chromatin preparation per cell
type (monocytes, PBLs, and DLD-1). Primer sequences
are listed in Additional file 6: Table S1. The library prepar-
ation protocol was adapted to make it compatible with the
large number of viewpoints. Details can be found in the
Additional file 2: Supplementary data, Methods.
Sequencing
Libraries were sequenced using the HiSeq2500 platform
(Illumina), producing single end reads of 50 bp.
Data analysis
The raw sequencing reads were de-multiplexed based on
viewpoint-specific primer sequences (the datasets are
accessible through GEO Series accession number
GSE89441). Reads were then trimmed to 16 bases and
mapped to an in silico generated library of fragends
(fragment ends) neighboring all DpnII sites in human
genome (NCBI37/hg19), using the custom Perl scripts.
No mismatches were allowed during the mapping and
the reads mapping to only one possible fragend were
used for further analysis. To create the 4C signal tracks
in the UCSC browser, we have generated the .*bed files
with information for each mappable fragend on the co-
ordinates and their covered/non-covered (1 or 0) status.
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Visualization of the tracks in the UCSC browser was
done with the following settings: windowing function:
mean; smoothing window: 12 pixels.
Identification of the interacting genes
First, we calculated the number of covered fragends
within a running window of k fragends throughout the
whole chromosome where the viewpoint is located. This
binary approach (i.e. a fragend is covered or is not
covered in the dataset) was chosen to overcome the
influence of polymerase chain reaction (PCR)-efficiency-
based biases, however this approach decreases the
dynamic range of the 4C-seq and may overestimate the
strength of distal interactions compared to proximal
interactions. The k was set separately for every viewpoint
so it contains on average 20 covered fragends in the area
around the viewpoint (+/– 100 kbp), e.g. when 100 out
of 150 fragends around the viewpoint were covered the
window size was set to 30 fragends. Next, we compared
the number of covered fragends in each running window
to the random distribution. The windows with a signifi-
cantly higher number of covered fragends compared to
random distribution (p < 10–8 based on binominal cumu-
lative distribution function; R pbinom) were considered
as a significant 4C signal. The following criteria were
defined for the identification of the candidate genes: (1)
the transcriptional start site (TSS) co-localizes with a
significant 4C-seq signal (p < 10–8) within 5 kbp; (2) the
susceptibility variant or other variant in linkage disequi-
librium (LD) co-localizes with the H3K27ac signal (that
marks activating regulatory elements) in the cell type from
which the 4C signal was obtained (68 loci in monocytes,
73 in lymphocytes, and 52 in intestinal epithelial cells) [9];
and (3) the gene is expressed (log2(RPKM) > –0.5) in the
assayed cell type (Additional file 1: Table S2). Datasets
used for expression analysis are listed in Additional file 7:
Table S3. Quality measures for the 4C library preparation
and sequencing can be found in Additional file 2:
Supplementary data, Figures S1–S3. The use of single
4C templates per cell type was validated in a bio-
logical duplicate of the lymphocyte 4C template that
is derived from a different donor (Additional file 2:
Figure S4A) and the reproducibility in other chromatin
interaction datasets was established by intersecting our
findings with two Hi-C datasets [25] (Additional file 2:
Figure S4B and Additional file 7: Table S3).
TSS occupancy by H3K27ac and H3K4me3
The publicly available datasets of H3K27ac and
H3K4me3 occupancy were accessed from the UCSC/
ENCODE browser (http://genome.ucsc.edu/ENCODE/).
Datasets are listed in Additional file 7: Table S3. The oc-
cupancy around 2 kbp +/– of TSS of was calculated
using custom Perl scripts and Cisgenome [55] functions.
eQTL analyses
GTEx
A manual look-up was performed for expression quantita-
tive trait loci (eQTL) in the Genotype-Tissue Expression
(GTEx) database (accession dates; eQTL-genes: 05-
2016; p values: 09-2016). The presence of eQTL genes
for each of the 92 IBD-associated SNPs was performed in
four different tissues: colon-transverse; colon-sigmoid;
small intestine-terminal ileum; and whole blood [38]. Next,
for each gene for which an IBD-associated SNP turned out
to be an eQTL, its presence among the 4C-seq identified
genes was evaluated (Additional file 3: Table S4). All tran-
scripts in the GTEx database that were not included in the
gene annotation (UCSC genes 2009) that was used for the
analysis of the 4C-seq data were removed from the analysis.
STAGE
eQTLs were analyzed using the Stockholm Atheroscler-
osis Gene Expression (STAGE) [39] dataset (Additional
file 2: Supplementary data, Methods). Identified loci
from GWAS for IBD were matched with imputed and ge-
notyped SNPs and were selected for eQTL discovery. We
compared the amount of eQTLs present in “SNP-candi-
date gene”-pairs and “SNP-control gene”-pairs. Control
genes are genes within the same locus that are not inter-
acting with the IBD-associated locus. An empirical false
discovery rate was estimated for each eQTL gene by shuf-
fling patient IDs 1000 times on genotype data as described
previously [56].
Gene set enrichment analysis (GSEA)
GSEA [40] was performed using gene expression
datasets [41] from intestinal biopsies obtained from ul-
cerative colitis patients (datasets available at GSE11223).
The “normal uninflamed sigmoid colon” and “UC in-
flamed sigmoid colon” were used and the fold changes
in expression were calculated using the GEO2R tool [57]
with default settings. Significance of the enrichment was
calculated based on 1000 cycles of permutations.
Signaling pathway analysis
The IL10 signaling pathway components were retrieved
from Ingenuity Pathway Analysis (IPA®, QIAGEN
Redwood City). Genes upregulated upon IL10 signaling
(target genes) and genes involved in the bilirubin cas-
cade were removed before further analysis. The interac-
tions between the members of the IL-10 signaling
pathway were visualized using the GeneMania tool
<http://www.genemania.org/>.
The general pathway analysis was performed with the
Ingenuity Pathway Analysis software (IPA®, QIAGEN
Redwood City), based on the candidate genes from the
three cell types, separately.
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Upstream regulators
Upstream regulators that are enriched regulators of the
candidate genes in our datasets were identified with the
Ingenuity Pathway Analysis software (IPA®, QIAGEN
Redwood City), based on the candidate genes from the
three cell types separately. The Ingenuity’s Upstream
Regulator Analysis algorithm predicts upstream regula-
tors from gene datasets based on the literature and
compiled in the Ingenuity knowledge base.
CTCF tracks
CTCF tracks were accessed from the UCSC/ENCODE
browser (http://genome.ucsc.edu/ENCODE/). Datasets
are listed in Additional file 7: Table S3.
Tracks used for rs630923 and rs2382817
All tracks were accessed from the UCSC/ENCODE
browser (http://genome.ucsc.edu/ENCODE/). Datasets
are listed in Additional file 7: Table S3. Haploblock
structures were visualized with Haploview [58]; pairwise
LD statistics of variants with a distance up to 500 kbp
were used in the analyses (Fig. 4, Additional file 2:
Supplementary data, Figure S9).
Organoid culture
Colon biopsies were obtained by colonoscopy. The biop-
sies were macroscopically and pathologically normal.
Crypt isolation and culture of human intestinal cells
from biopsies have been described previously [59, 60]. In
summary, human organoids were cultured in expansion
medium (EM) containing RSPO1, noggin, EGF, A83-01,
nicotinamide, SB202190, and WNT3A. The medium
was changed every 2–3 days and organoids were
passaged 1:4 every 9 days.
Five to seven days after passaging, the organoids were
exposed to 10 μL sterilized E. Coli-lysate (control orga-
noids were not stimulated). After 6 h of exposure, the
organoids were harvested and RNA was extracted using
TRIzol LS (Ambion™). Complementary DNA was syn-
thesized by performing reverse-transcription (iScript,
Biorad). Messenger RNA (mRNA) abundances were de-
termined by real-time PCR using primer pairs that target
HNF4α and NFKB1 (Additional file 6: Table S1) with the
SYBR Green method (Bio-Rad). ACTIN mRNA abun-
dance was used to normalize the data.
Additional files
Additional file 1: Table S2. 4C datasets. (XLSX 43677 kb)
Additional file 2: Supplementary data; Figures S1–S9 and Supplementary
Methods. (PDF 2295 kb)
Additional file 3: Table S4. eQTL analyses. (XLSX 16 kb)
Additional file 4: Table S5. Pathway analyses. (XLSX 65 kb)
Additional file 5: Table S6. Upstream regulators. (XLSX 135 kb)
Additional file 6: Table S1. Primer sequences. (XLSX 17 kb)
Additional file 7: Table S3. Publicly available datasets. (XLSX 11 kb)
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